Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Cluster analysis and display of genome-wide expression patterns

Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974

Tissue microarrays for high-throughput molecular profiling of tumor specimens

Kononen, J., Bubendorf, L., Kallionimeni, A., Barlund, M. T., Schraml, P., Leighton, S. B., Torhorst, J. K. H., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,101

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

Epidermal growth factor-related peptides and their receptors in human malignancies

Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,695

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605

Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells

Grygielewicz, P., Dymek, B., Bujak, A., Gunerka, P., Stanczak, A. M., Lamparska‐Przybysz, M., Wieczorek, M., Dzwonek, K., & Zdżalik-Bielecka, D. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0444-1 · Cited by 69

Distinctive E‐cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma

Müller, S., Su, L., Tighiouart, M., Saba, N. F., Zhang, H., Shin, D. M., & Chen, Z. (. (2008) · Cancer · doi:10.1002/cncr.23557 · Cited by 68

Expression of periostin in the serum of NSCLC and its function on proliferation and migration of human lung adenocarcinoma cell line (A549) in vitro

Hong, L., Sun, H., Lv, X., Yang, D., Zhang, J., & Shi, Y. P. (2009) · Molecular Biology Reports · doi:10.1007/s11033-009-9721-1 · Cited by 68

EMT tumorigenesis in the mouse mammary gland

Damonte, P., Gregg, J. P., Borowsky, A. D., Keister, B. A., & Cardiff, R. D. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700683 · Cited by 68

Mouse Mammary Tumor Biology: A Short History

Cardiff, R. D., & Kenney, N. J. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)98003-8 · Cited by 69

Molecular correlates of gefitinib responsiveness in human bladder cancer cells

Shrader, M., Pino, M. S., Brown, G. A., Black, P. C., Adam, L., Bar-Eli, M., Dinney, C. P., & McConkey, D. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0513 · Cited by 67

Targeting Notch to overcome radiation resistance

Yahyanejad, S., Theys, J., & Vooijs, M. (2015) · Oncotarget · doi:10.18632/oncotarget.6714 · Cited by 71

Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

Bunn, P. A., Dziadziuszko, R., Varella‐Garcia, M., Franklin, W. A., Witta, S. E., Kelly, K. L., & Hirsch, F. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0261 · Cited by 67

Evaluation of EML4-ALK Fusion Proteins in Non–Small Cell Lung Cancer Using Small Molecule Inhibitors

Li, Y., Ye, X., Liu, J., Zha, J., & Pei, L. (2011) · Neoplasia · doi:10.1593/neo.101120 · Cited by 66

Mechanisms of resistance to EGFR targeted therapies

Hrustanovic, G., Lee, B. J., & Bivona, T. G. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23627 · Cited by 67

Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells

Cufí, S., Bonavia, R., Vázquez‐Martín, A., Corominas-Faja, B., Oliveras‐Ferraros, C., Cuyàs, E., Martı́n-Castillo, B., Barrajón‐Catalán, E., Visa, J., Segura‐Carretero, A., et al. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.07.063 · Cited by 68

Molecular Predictors in Glioblastoma

Colman, H., & Aldape, K. (2008) · Archives of Neurology · doi:10.1001/archneur.65.7.877 · Cited by 65

Role of long non‐coding RNA in drug resistance in non‐small cell lung cancer

Wang, L., Ma, L., Xu, F., Zhai, W., Dong, S., Yin, L., Liu, J., & Yu, Z. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12652 · Cited by 65

Cytokines and Growth Factors Stimulate Hyaluronan Production: Role of Hyaluronan in Epithelial to Mesenchymal-Like Transition in Non-Small Cell Lung Cancer

Chow, G., Tauler, J., & Mulshine, J. L. (2010) · BioMed Research International · doi:10.1155/2010/485468 · Cited by 64

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives

Tomasello, C., Baldessari, C., Napolitano, M., Orsi, G., Grizzi, G., Bertolini, F., Barbieri, F., & Cascinu, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.013 · Cited by 65

Resistance to molecularly targeted therapy in non-small-cell lung cancer

Asao, T., Takahashi, F., & Takahashi, K. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.09.001 · Cited by 62

Contribution of Epithelial Plasticity to Therapy Resistance

Santamaría, P. G., Moreno‐Bueno, G., & Cano, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050676 · Cited by 66

Effects of the HIF-1α and NF-κB loop on epithelial-mesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells

Cheng, Z., Wang, D., LIU, T., Liu, W., Xia, W.-B., XU, J., ZHANG, Y.-H., Qu, Y., Guo, L., Ding, L., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3022 · Cited by 65

4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors

Tan, L., Zhang, Z., Gao, D., Luo, J., Tu, Z., Li, Z., Peng, L., Ren, X., & Ding, K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00608 · Cited by 61

CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC

Becker, J. H., Gao, Y., Soucheray, M., Pulido, I., Kikuchi, E., Rodríguez, M. L., Gandhi, R., Lafuente-Sanchis, A., Aupí, M., Fernández-Coronado, J. A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0024 · Cited by 59

Inducible expression of TGFβ, Snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model

Argast, G. M., Krueger, J. S., Thomson, S., Sujka-Kwok, I., Carey, K., Silva, S., O’Connor, M., Mercado, P., Mulford, I. J., Young, G. D., et al. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9394-8 · Cited by 61

The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer

Ray, M., Salgia, R., & Vokes, E. E. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0054 · Cited by 60

Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition

Lou, W., Chen, Y., Zhu, K., Deng, H., Wu, T., & Wang, J. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00271 · Cited by 62

Acquired resistance to 5-fluorouracilviaHSP90/Src-mediated increase in thymidylate synthase expression in colon cancer

Ahn, J.-Y., Lee, J., Min, H., & Lee, H. (2015) · Oncotarget · doi:10.18632/oncotarget.5327 · Cited by 63

Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features

Sato, H., Shien, K., Tomida, S., Okayasu, K., Suzawa, K., Hashida, S., Torigoe, H., Watanabe, M., Yamamoto, H., Soh, J., et al. (2017) · Scientific Reports · doi:10.1038/srep40847 · Cited by 61

MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type

Li, J., Li, X., Ren, S., Chen, X., Zhang, Y., Zhou, F., Zhao, M., Zhao, C., Chen, X., Cheng, N., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2302 · Cited by 57

Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity

Basu, D., Nguyen, T.-T. K., Montone, K. T., Zhang, G., Wang, L.-P., Diehl, J. A., Rustgi, A. K., Lee, J. T., Weinstein, G. S., & Herlyn, M. (2010) · Oncogene · doi:10.1038/onc.2010.170 · Cited by 58

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors

Gray, J. E., Haura, E. B., Chiappori, A., Tanvetyanon, T., Williams, C. C., Pinder-Schenck, M. C., Kish, J. A., Kreahling, J. M., Lush, R. M., Neuger, A. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2235 · Cited by 58

Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer

Matsuda, N., Lim, B., Wang, X., & Ueno, N. T. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1299707 · Cited by 58

Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance

Krysan, K., Lee, J. M., Dohadwala, M., Gardner, B. K., Reckamp, K. L., Garon, E. B., John, M. A. S., Sharma, S. P., & Dubinett, S. M. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181630ece · Cited by 58

The Pathology of EMT in Mouse Mammary Tumorigenesis

Cardiff, R. D. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9184-y · Cited by 57

Membrane-Bound Heparin-Binding Epidermal Growth Factor–Like Growth Factor Regulates E-Cadherin Expression in Pancreatic Carcinoma Cells

Wang, F., Sloss, C. M., Zhang, X., Lee, S. W., & Cusack, J. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0498 · Cited by 56

Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial–mesenchymal transition

Lin, S. H., Wang, J., Saintigny, P., Wu, C.-C., Giri, U. P., Zhang, J., Menju, T., Diao, L., Byers, L. A., Weinstein, J. N., et al. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-1079 · Cited by 54

Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR–TKI Tolerance and Lung Cancer Dissemination

Kuo, M.-H., Lee, A.-C., Hsiao, S.-H., Lin, S., Chiu, Y.-F., Yang, L.-H., Yu, C.-C., Chiou, S., Huang, H., Ko, J., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3228 · Cited by 53

The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies

Laface, C., Maselli, F. M., Santoro, A. N., Iaia, M. L., Ambrogio, F., Laterza, M., Guarini, C., Santis, P. D., Perrone, M., & Fedele, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061604 · Cited by 63

Oncolytic adenoviruses targeted to cancer stem cells

Short, J. J., & Curiel, D. T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0367 · Cited by 54

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

Morgillo, F., Cascone, T., D’Aiuto, E., Martinelli, E., Troiani, T., Saintigny, P., Palma, R. D., Heymach, J. V., Berrino, L., Tuccillo, C., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.244 · Cited by 53

Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition

Lowes, L. E., & Allan, A. L. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2017.10.004 · Cited by 54

Partial EMT in Squamous Cell Carcinoma: A Snapshot

Liao, C., Wang, Q., An, J., Long, Q., Wang, H., Xiang, M., Xiang, M., Zhao, Y., Liu, Y., Liu, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.61566 · Cited by 55

Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma

Marijon, H., Dokmak, S., Paradis, V., Zappa, M., Bièche, I., Bouattour, M., Raymond, É., & Faivre, S. J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.011 · Cited by 52

PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGFα

Dopeso, H., Jiao, H., Cuesta, Á. M., Henze, A., Jurida, L., Kracht, M., Acker‐Palmer, A., Garvalov, B. K., & Acker, T. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1346 · Cited by 52

The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy.

Richardson, F. C., Young, G. D., Sennello, R., Wolf, J. L., Argast, G. M., Mercado, P., Davies, A. M., Epstein, D. M., & Wacker, B. (2012) · PubMed · Cited by 51

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification

Monica, S. L., Caffarra, C., Saccani, F., Galvani, E., Galetti, M., Fumarola, C., Bonelli, M. A., Cavazzoni, A., Cretella, D., Sirangelo, R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078656 · Cited by 52

MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling

Koo, T., Cho, B. J., Kim, D. H., Park, J. M., Choi, E. J., Kim, H. H., Lee, D. J., & Kim, I. A. (2017) · Oncotarget · doi:10.18632/oncotarget.18924 · Cited by 51

Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2

Xu, G., Yu, H., Shi, X., Sun, L., Zhou, Q., Zheng, D., Shi, H., Li, N., Zhang, X., & Shao, G. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-174 · Cited by 51

Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms

Grillo, F., Florio, T., Ferraù, F., Kara, E., Fanciulli, G., Faggiano, A., Colao, A. A. L., & _, _. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0531 · Cited by 50

Clinical implications of epithelial cell plasticity in cancer progression

Aparicio, L. A., Blanco, M., Castosa, R., Concha, Á., Valladares, M., Calvo, L., & Figueroa, A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.007 · Cited by 49

Epithelial to Mesenchymal Transition Tumors: Fallacious or Snail's Pace?

Cardiff, R. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2250 · Cited by 49

Fhit Regulates EMT Targets through an EGFR/Src/ERK/Slug Signaling Axis in Human Bronchial Cells

Joannes, A., Grelet, S., Duca, L., Gilles, C., Kileztky, C., Dalstein, V., Birembaut, P. L., Polette, M., & Nawrocki‐Raby, B. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0386-t · Cited by 49

SUV420H2 is an epigenetic regulator of epithelial/mesenchymal states in pancreatic cancer

Viotti, M., WILSON, C. A., McCleland, M. L., Koeppen, H., Haley, B., Jhunjhunwala, S., Klijn, C. N., Modrusan, Z. D., Arnott, D. P., Classon, M., et al. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201705031 · Cited by 49

Loss of epidermal growth factor receptor expression in oral squamous cell carcinoma is associated with invasiveness and epithelial-mesenchymal transition

Kimura, I., Kitahara, H., Ooi, K., Kato, K., NOGUCHI, N., Yoshizawa, K., Nakamura, H., & Kawashiri, S. (2015) · Oncology Letters · doi:10.3892/ol.2015.3833 · Cited by 48

Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes

Wallin, J. J., Guan, J., Edgar, K. A., Zhou, W., Francis, R., Torres, A. C., Haverty, P. M., Eastham‐Anderson, J., Arena, S., Bardelli, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036402 · Cited by 50

Fibroblast Growth Factor Signaling in Non–Small-Cell Lung Cancer

Semrad, T. J., & Mack, P. C. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.08.001 · Cited by 48

A Compendium of the Mouse Mammary Tumor Biologist: From the Initial Observations in the House Mouse to the Development of Genetically Engineered MicePreprint

Cardiff, R. D., & Kenney, N. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003111 · Cited by 48

Identifying transcriptional programs underlying cancer drug response with TraCe-seq

Chang, M. T., Shanahan, F., Nguyen, T. T. T., Staben, S. T., Gazzard, L. J., Yamazoe, S., Wertz, I. E., Piskol, R., Yang, Y. A., Modrusan, Z. D., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01005-3 · Cited by 42

1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment

Upadhyay, S. K., Verone, A. R., Shoemaker, S. F., Qin, M., Liu, S., Campbell, M. J., & Hershberger, P. A. (2013) · Cancers · doi:10.3390/cancers5041504 · Cited by 46

A pan-HER approach for cancer therapy: background, current status and future development

Huang, Z., Brdlik, C. M., Jin, P., & Shepard, H. M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802630427 · Cited by 45

Clinical Significance of Thyroid Transcription Factor-1 in Advanced Lung Adenocarcinoma Under Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment

Chung, K., Huang, Y., Chang, Y., Yu, C., Yang, C.-H., Chang, Y., Shih, J., & Yang, P. (2011) · CHEST Journal · doi:10.1378/chest.10-3149 · Cited by 47

N-Myc down regulation induced differentiation, early cell cycle exit, and apoptosis in human malignant neuroblastoma cells having wild type or mutant p53

Janardhanan, R., Banik, N. L., & Ray, S. K. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.06.009 · Cited by 47

A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer

Gold, K. A., Lee, J. J., Harun, N., Tang, X., Price, J., Kawedia, J. D., Tran, H. T., Erasmus, J. J., Blumenschein, G. R., William, W. N., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0228 · Cited by 46

Crosstalk between Epidermal Growth Factor Receptors (EGFR) and integrins in resistance to EGFR tyrosine kinase inhibitors (TKIs) in solid tumors

Javadi, S., Zhiani, M., Mousavi, M. A., & Fathi, M. (2020) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2020.151083 · Cited by 44

Alteration of the E-Cadherin/β-Catenin Complex Is an Independent Poor Prognostic Factor in Lung Adenocarcinoma

Kim, H., Yoo, S. B., Sun, P., Jin, Y., Jheon, S., Lee, C. T., & Chung, J.-H. (2013) · Journal of Pathology and Translational Medicine · doi:10.4132/koreanjpathol.2013.47.1.44 · Cited by 45

Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas

Basu, D., Montone, K. T., Wang, L., Gimotty, P. A., Hammond, R., Diehl, J. A., Rustgi, A. K., Lee, J. T., Räsänen, K., Weinstein, G. S., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.12.15883 · Cited by 44

Entinostat (SNDX-275) for the treatment of non-small cell lung cancer

Ruiz, R., Raez, L. E., & Rolfo, C. D. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1056779 · Cited by 44

TGF-β/SMAD3 Pathway Stimulates Sphingosine-1 Phosphate Receptor 3 Expression IMPLICATION OF SPHINGOSINE-1 PHOSPHATE RECEPTOR 3 IN LUNG ADENOCARCINOMA PROGRESSION

Zhao, J., Liu, J., Lee, J.-F., Zhang, W., Kandouz, M., VanHecke, G. C., Chen, S., Ahn, Y., Lonardo, F., & Lee, M.-J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.740084 · Cited by 45

MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties

Tominaga, E., Yuasa, K., Shimazaki, S., & Hijikata, T. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.10.015 · Cited by 42

Epidermal growth factor receptor and K‐Ras mutations and resistance of lung cancer to insulin‐like growth factor 1 receptor tyrosine kinase inhibitors

Kim, W., Prudkin, L., Feng, L., Kim, E. S., Hennessy, B. T., Lee, J., Lee, J. J., Glisson, B. S., Lippman, S. M., Wistuba, I. I., et al. (2012) · Cancer · doi:10.1002/cncr.26656 · Cited by 42

Radiogenomic Analysis Demonstrates Associations between18F-Fluoro-2-Deoxyglucose PET, Prognosis, and Epithelial-Mesenchymal Transition in Non–Small Cell Lung Cancer

Yamamoto, S., Huang, D., Du, L., Korn, R. L., Jamshidi, N., Burnette, B., & Kuo, M. (2016) · Radiology · doi:10.1148/radiol.2016160259 · Cited by 43

Epithelial contribution to the profibrotic stiff microenvironment and myofibroblast population in lung fibrosis

Gabasa, M., Duch, P., Jorba, I., Giménez, A., Lugo, R., Pavelescu, I., Rodríguez‐Pascual, F., Molina‐Molina, M., Xaubet, A., Pereda, J., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-01-0026 · Cited by 42

Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer

Liu, C., Shaurova, T., Shoemaker, S. F., Petkovich, M. P., Hershberger, P. A., & Wu, Y. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00307 · Cited by 42

Fucoidan increased the sensitivity to gefitinib in lung cancer cells correlates with reduction of TGFβ-mediated Slug expression

Qiu, W.-L., Tseng, A.-J., Hsu, H.-Y., Hsu, W.-H., Lin, Z., Hua, W.-J., & Lin, T. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.03.066 · Cited by 42

Tumor mRNA Expression Profiles Predict Responses to Chemotherapy

Minna, J. D., Girard, L., & Xie, Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3968 · Cited by 42

The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors

Belani, C. P. (2010) · Cancer Investigation · doi:10.3109/07357901003631072 · Cited by 41

Molecular Predictors of Sensitivity to the MET Inhibitor PHA665752 in Lung Carcinoma Cells

Matsubara, D., Ishikawa, S., Oguni, S., Aburatani, H., Fukayama, M., & Niki, T. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e2a409 · Cited by 41

ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC)

Witta, S. E., Dziadziuszko, R., Yoshida, K., Hedman, K., Varella‐Garcia, M., Bunn, P. A., & Hirsch, F. R. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn703 · Cited by 41

Cancer stem cells: an insight into the development of metastatic tumors and therapy resistance

Nairuz, T., Mahmud, Z., Manik, M. R. K., & Kabir, Y. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10529-x · Cited by 43

Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors

Ghosh, G., Lian, X. L., Kron, S. J., & Palecek, S. P. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-95 · Cited by 39

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients

Ruiz, M. I. G., Floor, K., Steinberg, S. M., Grünberg, K., Thunnissen, E., Beliën, J. A. M., Meijer, G. A., Peters, G. J., Smit, E. F., Rodríguez, J. A., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604781 · Cited by 41

Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.

Majem, M., & Remón, J. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.09 · Cited by 41

Differential sensitivity of A549 non small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors

Jaramillo, M., Banville, M., Collins, C., Paul‐Roc, B., Bourget, L., & O'Connor‐McCourt, M. D. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.4.5533 · Cited by 39

Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT

Li, D., Zhang, L., Zhou, J., & Chen, H. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.12.007 · Cited by 39

Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

Leighl, N. B., Rizvi, N. A., de Lima, L. G., Arpornwirat, W., Rudin, C. M., Chiappori, A., Ahn, M., Chow, L. Q. M., Bazhenova, L. A., Dechaphunkul, A., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.07.007 · Cited by 39

Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2‐positive breast cancer

Martínez, V. G., Crown, J. P., Porter, R. K., & O’Driscoll, L. (2017) · International Journal of Cancer · doi:10.1002/ijc.30705 · Cited by 39

Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data

Mountzios, G., Dimopoulos, M. A., Soria, J., Sanoudou, D., & PAPADIMITRIOU, C. A. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.10.002 · Cited by 40

Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2

Hesketh, P. J., Chansky, K., Wozniak, A. J., Hirsch, F. R., Spreafico, A., Moon, J., Mack, P. C., Marchello, B. T., Franklin, W. A., Crowley, J. J., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318183aa1f · Cited by 39

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models

Pitts, T. M., Kulikowski, G. N., Tan, A. C., Murray, B. W., Arcaroli, J. J., Tentler, J. J., Spreafico, A., Selby, H. M., Kachaeva, M. I., McPhillips, K. L., et al. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00035 · Cited by 39

Energy sources identify metabolic phenotypes in pancreatic cancer

Liang, C., Qin, Y., Zhang, B., Ji, S., Shi, S., Xu, W., Liu, J., Xiang, J., Liang, D., Hu, Q., et al. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmw097 · Cited by 37

Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies

Asić, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.004 · Cited by 38

Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling

Machida, K., Eschrich, S. A., Li, J., Bai, Y., Koomen, J. M., Mayer, B. J., & Haura, E. B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013470 · Cited by 38

KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations

O’Hagan, R. C., & Heyer, J. (2011) · Genes & Cancer · doi:10.1177/1947601911408080 · Cited by 38

Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer

Lara-Guerra, H., Chung, C. T. ‐., Schwock, J., Pintilie, M., Hwang, D. M., Leighl, N. B., Waddell, T. K., & Tsao, M. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.10.020 · Cited by 38

Histopathological Determinants of Tumor Resistance: A Special Look to the Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers

Ilardi, G., Zambrano, N., Merolla, F., Siano, M., Varricchio, S., Vecchione, M. L., Rosa, G. D., Mascolo, M., & Staibano, S. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113209990227 · Cited by 38

Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer

Fujiwara, A., Shintani, Y., Funaki, S., Kawamura, T., Kimura, T., Minami, M., & Okumura, M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.01.006 · Cited by 37

EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency

Fu, W., Lei, C., Yu, Y., Liu, S., Li, T., Lin, F., Fan, X., Shen, Y., Ding, M., Tang, Y. F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2732 · Cited by 37

MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process

Wang, H., Liu, Y.-N., Wu, S., Hsu, C., Chang, T., Tsai, M., Lin, Y., & Shih, J. (2020) · Cancer Biomarkers · doi:10.3233/cbm-191119 · Cited by 37

Pharmacogenetics of EGFR in Lung Cancer: Perspectives and Clinical Applications

Mayo, C., Bertrán-Alamillo, J., Molina‐Vila, M. Á., Giménez-Capitán, A. A., Costa, C., & Rosell, R. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.54 · Cited by 36

FBW7 Upregulation Enhances Cisplatin Cytotoxicity in Non-small Cell Lung Cancer Cells

Yu, H., Wei, W., Xia, L.-H., Han, W., Zhao, P., Wu, S., Li, W., & Chen, W. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.11.6321 · Cited by 36

Genome Wide Methylome Alterations in Lung Cancer

Mullapudi, N., Ye, B., Suzuki, M., Fazzari, M. J., Han, W., Shi, M. K., Marquardt, G., Lin, J., Wang, T., Keller, S. M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143826 · Cited by 36

Hydrogen peroxide-producing NADPH oxidases and the promotion of migratory phenotypes in cancer

Meitzler, J. L., Konaté, M. M., & Doroshow, J. H. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108076 · Cited by 37

The Autophagic Route of E-Cadherin and Cell Adhesion Molecules in Cancer Progression

Santarosa, M., & Maestro, R. (2021) · Cancers · doi:10.3390/cancers13246328 · Cited by 39

Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition

Thomson, S., Buck, E. A., Petti, F., Griffin, G., Brown, E., Ramnarine, N., Iwata, K. K., Gibson, N. W., & Haley, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1058 · Cited by 663

Erlotinib sensitivity in NSCLC cell lines correlates with an epithelial to mesenchymal transition which induces a switch in receptor tyrosine kinase signaling.

Thomson, S., Petti, F., Sujka-Kwok, I., Buck, E. A., Barr, S. M., Miglarese, M. R., & Haley, J. D. (2007) · Molecular Cancer Therapeutics

Abstract 5063: Preclinical evaluation of an EMT multi-gene biomarker index for predicting response to inhibitors of EGFR and IGF1R

Argast, G. M., Bean, J. M., Wang, J., O'Connor, M., Feng, B., Nicoletti, R., Lerner, L. R., Heyer, J., Chiu, M. I., Robinson, M. O., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-5063

Epithelial to mesenchymal markers and clinical outcomes on erlotinib in stage IV non-small cell lung cancer patients.

Pool, M. D., Fidler, M. J., Basu, S., Mahon, B., Buckingham, L. E., Walters, K. K., Batus, M., Hensing, T. A., Borgia, J. A., & Bonomi, P. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.e19117

P3-015: Clinicopathologic features and epidermal growth factor receptor mutations associated with epithelial-mesenchymal transition in non-small cell lung cancer

Zhou, C., Deng, Q., & Su, C. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000283501.96516.b4